Atria Investments Inc Acquires 1,378 Shares of Vericel Co. (NASDAQ:VCEL)

Atria Investments Inc raised its stake in Vericel Co. (NASDAQ:VCEL) by 21.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,768 shares of the biotechnology company’s stock after acquiring an additional 1,378 shares during the quarter. Atria Investments Inc’s holdings in Vericel were worth $328,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. International Assets Investment Management LLC increased its position in Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 619 shares in the last quarter. CWM LLC increased its holdings in shares of Vericel by 319.0% during the second quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock worth $30,000 after buying an additional 504 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Vericel by 48.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 405 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 322 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its position in Vericel by 9.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 220 shares during the last quarter.

Analyst Ratings Changes

VCEL has been the subject of several research reports. TD Cowen increased their target price on Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. Canaccord Genuity Group reiterated a “buy” rating and set a $60.00 target price on shares of Vericel in a research report on Tuesday. Canaccord Genuity Group assumed coverage on shares of Vericel in a report on Friday, August 9th. They set a “buy” rating and a $57.00 target price on the stock. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. Finally, Stephens boosted their price objective on shares of Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Vericel has an average rating of “Moderate Buy” and an average price target of $58.14.

Vericel Price Performance

Shares of NASDAQ:VCEL opened at $59.11 on Friday. Vericel Co. has a 1 year low of $32.31 and a 1 year high of $60.15. The business’s 50-day moving average is $46.13 and its 200-day moving average is $47.02. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of 985.33 and a beta of 1.66.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. The firm had revenue of $57.91 million for the quarter, compared to analysts’ expectations of $55.32 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%. Analysts anticipate that Vericel Co. will post 0.13 EPS for the current year.

Insider Buying and Selling at Vericel

In other news, Director Steven C. Gilman sold 5,833 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total transaction of $235,361.55. Following the completion of the sale, the director now owns 11,000 shares in the company, valued at $443,850. The trade was a 34.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the sale, the chief executive officer now directly owns 220,937 shares of the company’s stock, valued at approximately $9,142,373.06. The trade was a 7.34 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,166 shares of company stock valued at $1,200,764. Corporate insiders own 5.20% of the company’s stock.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.